Related Experiment Video
Updated: Jul 6, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Gaucher disease: unmet treatment needs
1Lysosomal Storage Disorders Unit, Department of Haematology, Royal Free Hospital and University College Medical School, London, UK. atul.mehta@royalfree.nhs.uk
Acta Paediatrica (Oslo, Norway : 1992)
|May 28, 2008
Summary
Enzyme replacement therapy (ERT) is effective for Gaucher disease, but unmet needs persist. New treatments are developing, yet understanding disease mechanisms is crucial for progress.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Background:
- Gaucher disease is a genetic disorder caused by deficient lysosomal glucocerebrosidase.
- Key manifestations include enlarged spleen and liver, low blood counts, and bone problems.
- Current treatments like enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) show efficacy but have limitations.
Purpose of the Study:
- To review the current understanding of Gaucher disease.
- To highlight the effectiveness and limitations of existing treatments.
- To discuss emerging therapies and unmet needs in Gaucher disease management.
Main Methods:
- Literature review of Gaucher disease pathophysiology and treatment.
- Analysis of clinical data on enzyme replacement therapy and substrate reduction therapy.
- Exploration of novel therapeutic approaches and their potential.
Main Results:
- ERT and SRT improve organomegaly, anemia, and thrombocytopenia in Gaucher disease patients.
- Unmet needs include treatment accessibility, disease site penetration, and management of malignancies.
- Neurological symptoms in type 1 Gaucher disease are not improved by current ERT or SRT.
Conclusions:
- Enzyme replacement therapy remains the primary treatment for Gaucher disease.
- Emerging therapies, including small molecules, offer potential for improved tissue penetration.
- A deeper understanding of Gaucher disease's underlying mechanisms is essential for advancing treatment strategies.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...